 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Pharmacy Clinical Coordinator — Surgery, Department of Pharmacy, Wake Forest University Baptist Medical Center, Winston-Salem, NC
Associate Professor, Department of Anesthesiology and Internal Medicine, School of Medicine, Wake Forest University
Assistant Professor, Department of Cardiothoracic Surgery, School of Medicine, Wake Forest University
Assistant Professor, Department of Anesthesiology, School of Medicine, Wake Forest University
Reprints: Marc G Reichert PharmD BCPS, Department of Pharmacy, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157-1163, FAX 336/713-3401, E-mail reichert{at}wfubmc.edu
OBJECTIVE: To report 4 patients who became excessively anticoagulated with the recommended or lower starting doses of argatroban during treatment for heparin-induced thrombocytopenia type II (HIT-II) in a cardiothoracic intensive care unit.
CASE SUMMARY: Four patients were treated with argatroban after confirmation of HIT-II after cardiac surgery. In 3 patients, argatroban was initiated at the recommended starting dose of 2 µg/kg/min; in 1 patient, therapy was initiated at 1 µg/kg/min. All patients had relatively normal hepatic function. In all cases, the resulting activated partial thromboplastin time was supertherapeutic and exceeded 100 seconds in 3 patients. Additionally, argatroban clearance appeared to be prolonged upon discontinuation.
DISCUSSION: Argatroban pharmacokinetics in critically ill patients have not been investigated. Our case series demonstrates the potential over-anticoagulation that can occur in this patient population despite relatively normal hepatic function. An objective causality assessment revealed that the adverse drug event in these patients was probably caused by administration of argatroban.
CONCLUSIONS: Formal pharmacokinetic studies of argatroban are needed in critically ill patients in order to optimize therapy.
Key Words: argatroban, cardiac surgery, heparin-induced thrombocytopenia
Published Online, March 25, 2003. www.theannals.com, DOI 10.1345/aph.1C187
This article has been cited by other articles:
|
|
 |
|
  A. J Ansara, S. Arif, and R. D Warhurst Weight-Based Argatroban Dosing Nomogram for Treatment of Heparin-Induced Thrombocytopenia Ann. Pharmacother., January 1, 2009; 43(1): 9 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P Keegan, E. M Gallagher, N. E Ernst, E. J Young, and E. W Mueller Effects of Critical Illness and Organ Failure on Therapeutic Argatroban Dosage Requirements in Patients with Suspected or Confirmed Heparin-Induced Thrombocytopenia Ann. Pharmacother., January 1, 2009; 43(1): 19 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Begelman, S. B. Baghdasarian, I. M. Singh, M. A. Militello, M. J. Hursting, and J. R. Bartholomew Argatroban Anticoagulation in Intensive Care Patients: Effects of Heart Failure and Multiple Organ System Failure J Intensive Care Med, September 1, 2008; 23(5): 313 - 320. [Abstract] [PDF]
|
|
|
|
 |
|
 T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 340S - 380S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E Dager Considerations for Drug Dosing Post Coronary Artery Bypass Graft Surgery Ann. Pharmacother., March 1, 2008; 42(3): 421 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. D Hoffman, Y. Czyz, D. A McCollum, and M. J Hursting Reduced Argatroban Doses After Coronary Artery Bypass Graft Surgery Ann. Pharmacother., March 1, 2008; 42(3): 309 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gray, D. E. Wallis, M. J. Hursting, E. Katz, and B. E. Lewis Argatroban Therapy for Heparin-Induced Thrombocytopenia in Acutely Ill Patients Clinical and Applied Thrombosis/Hemostasis, October 1, 2007; 13(4): 353 - 361. [Abstract] [PDF]
|
|
|
|
 |
|
 J. H. Levy, K. A. Tanaka, and M. J. Hursting Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia Anesth. Analg., September 1, 2007; 105(3): 570 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Koster, S. Buz, R. Hetzer, H. Kuppe, K. Breddin, and S. Harder Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: First results from the ARG-E03 trial. J. Thorac. Cardiovasc. Surg., September 1, 2006; 132(3): 699 - 700. [Full Text] [PDF]
|
|
|
|
|
|
S. Kodityal, P. H. Nguyen, A. Kodityal, J. Sherer, M. J. Hursting, and L. Rice Argatroban for Suspected Heparin-Induced Thrombocytopenia: Contemporary Experience at a Large Teaching Hospital J Intensive Care Med, March 1, 2006; 21(2): 86 - 92. [Abstract] [PDF]
|
|
|
|
|
|
A. J Yee and D. J Kuter Successful Recovery After an Overdose of Argatroban Ann. Pharmacother., February 1, 2006; 40(2): 336 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. V Reddy, E. J Grossman, S. A Trevino, M. J Hursting, and P. T Murray Argatroban Anticoagulation in Patients with Heparin-Induced Thrombocytopenia Requiring Renal Replacement Therapy Ann. Pharmacother., October 1, 2005; 39(10): 1601 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W Kubiak, P. M Szumita, and J. R Fanikos Extensive Prolongation of aPTT with Argatroban in an Elderly Patient with Improving Renal Function, Normal Hepatic Enzymes, and Metastatic Lung Cancer Ann. Pharmacother., June 1, 2005; 39(6): 1119 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Gasparovic, N. S. Nathan, D. Fitzgerald, and S. F. Aranki Severe Argatroban-Induced Coagulopathy in a Patient With a History of Heparin-Induced Thrombocytopenia Ann. Thorac. Surg., December 1, 2004; 78(6): e89 - e91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E Dager and R. H White Argatroban for Heparin-Induced Thrombocytopenia in Hepato-Renal Failure and CVVHD Ann. Pharmacother., September 1, 2003; 37(9): 1232 - 1236. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
